Journal of Hypertension最新文献

{"title":"Long-term event rates, risk factors, and treatment pattern in 1.4 million individuals qualifying for dual blood pressure lowering therapy.","authors":"Antonio Coca, Claudio Borghi, George S Stergiou, Nelly Francoise Ly, Christopher Lee, Aurore Tricotel, Anna Castelo-Branco, Irfan Khan, Jacques Blacher, Mohamed Abdel-Moneim","doi":"10.1097/HJH.0000000000004002","DOIUrl":"10.1097/HJH.0000000000004002","url":null,"abstract":"<p><strong>Objectives: </strong>We assessed rates of cardiovascular events, all-cause death, baseline risk factors, and treatment patterns in a population qualifying for initiation of dual combination blood pressure (BP)-lowering therapy. We also evaluated the association between dual versus monotherapy during follow-up and incidence of cardiovascular events.</p><p><strong>Methods: </strong>This study utilized integrated databases in England: Clinical Practice Research Datalink, Hospital Episode Statistics, and Office for National Statistics. Individuals aged at least 18 years qualifying for dual therapy were identified during 15-year period (2005-2019). The primary endpoint was composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, and cardiovascular death. The secondary endpoint was all-cause death.</p><p><strong>Results: </strong>Total 1 426 079 individuals met selection criteria. The 15-year event rates for the primary and secondary endpoints were 27.1 and 32.6%, respectively. Atherosclerotic cardiovascular disease, diabetes on insulin therapy, heart failure, atrial fibrillation, chronic kidney disease, and advanced age were associated with two to four-fold higher risk of primary and secondary endpoints. The estimated hazard ratio for dual versus monotherapy as a time-varying covariate was 0.82 (95% confidence interval 0.81-0.83) for the primary endpoint. At variance with guidelines, monotherapy was most common treatment pattern over 5-year follow-up.</p><p><strong>Conclusion: </strong>Baseline characteristics conveying a multifold higher risk for cardiovascular events and all-cause death mostly represented nonmodifiable risk factors. Treatment with dual therapy as compared to monotherapy was associated with reduction in cardiovascular events. Monotherapy remained most common BP-lowering treatment indicating substantial opportunity for risk reduction by treatment intensification.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"993-1002"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical appraisal of antihypertensive therapy in psoriasis: limitations and future directions.","authors":"Ibrahim Nagmeldin Hassan","doi":"10.1097/HJH.0000000000004016","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004016","url":null,"abstract":"","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":"43 6","pages":"1086"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell adhesion molecules and incident hypertension in black and white adults: the REGARDS study.","authors":"Tyler Harkness, Katherine Wilkinson, Ying K Loo, Virginia J Howard, Mary Cushman, Neil A Zakai, Katharine L Cheung, Suzanne E Judd, Timothy B Plante","doi":"10.1097/HJH.0000000000004004","DOIUrl":"10.1097/HJH.0000000000004004","url":null,"abstract":"<p><strong>Background: </strong>Higher C-reactive protein-quantified inflammation associates with greater incident hypertension risk. E-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1) are cell adhesion molecules that aid leukocyte adhesion during inflammation. Their association with incident hypertension is unclear.</p><p><strong>Methods: </strong>REGARDS enrolled 30 239 Black and White US adults aged ≥45 years from across the contiguous United States in 2003-2007, with a second exam in 2013-2016. The Biomarkers as Mediators of Racial Disparities in Risk Factors (BioMedioR) study included 4400 REGARDS participants who attended both exams. We excluded participants with hypertension or missing biomarkers at baseline. Hypertension used a 140/90 mmHg threshold or self-reported use of blood pressure (BP) lowering medications. Modified Poisson regression estimated relative risk (RR) of incident hypertension by tertile of baseline E-Selectin, ICAM-1, and VCAM-1.</p><p><strong>Results: </strong>Among 1879 nonhypertensive participants (mean [SD] age 62 [8] years, 25% Black race, 55% women) with 9 years median follow up, 36% developed hypertension. E-selectin and ICAM-1 were higher among Black participants; VCAM-1 was higher among White participants. Higher E-selectin was associated with greater risk of incident hypertension among White but not Black adults in some models (e.g., minimally adjusted: RR 1.27; 95% confidence interval (CI) 1.04-1.44 comparing tertile 3 vs. 1) ICAM-1 was associated with greater hypertension risk in only an unadjusted model.</p><p><strong>Conclusion: </strong>In a prospective study of Black and White US adults, E-selectin was associated with incident hypertension among White adults and ICAM-1 in White and Black adults in partially or unadjusted models. Modification of E-selectin might be tested to lower risk of hypertension development.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1012-1020"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing the paradigm of long-term blood pressure control: a systematic review of novel therapies.","authors":"Sonali R Gnanenthiran, Sabrina Delgado, Katrina M Mirabito Colafella, Markus P Schlaich, Aletta E Schutte, Anthony Rodgers","doi":"10.1097/HJH.0000000000003984","DOIUrl":"https://doi.org/10.1097/HJH.0000000000003984","url":null,"abstract":"<p><p>Novel drug and device therapies have the potential to achieve long-term control of blood pressure (BP) and thereby overcome the barriers of nonadherence and undertreatment. We propose that ideal BP lowering therapy should meet six key criteria: (i) achieve a clinically relevant BP reduction; (ii) durable BP reduction; (iii) be well tolerated; (iv) have the ability to be safely combined with other BP lowering treatments; (v) have high patient acceptability and (vi) be cost-effective and simple to use to maximize scalability. In this paper, we systematically review emerging solutions for long-term control of BP including antibody-based therapies, sRNA therapies, and DNA-based gene editing which target the renin angiotensin system, and implant therapies, and interventional approaches (renal denervation and baroreceptor activation therapies). These novel therapies may substantially complement and, in some settings, even replace current antihypertensive therapies. Implementation will require significant progress in overcoming technological-, systems-, prescriber- and patient-level barriers.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":"43 6","pages":"917-928"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The bidirectional link between left ventricular hypertrophy and chronic kidney disease. A cross lagged analysis.","authors":"Eva Ntounousi, Graziella D'Arrigo, Mercedes Gori, Giovanni Bruno, Francesca Mallamaci, Giovanni Tripepi, Carmine Zoccali","doi":"10.1097/HJH.0000000000004001","DOIUrl":"10.1097/HJH.0000000000004001","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is known to reduce glomerular filtration rate (GFR), while chronic kidney disease (CKD) significantly increases the risk of left ventricular hypertrophy (LVH) and HF. Although these connections have been explored in separate studies, comprehensive research examining the mutual links between CKD and LVH progression is lacking.</p><p><strong>Methods: </strong>Our study investigates the longitudinal relationship between estimated GFR (eGFR) and left ventricular mass index (LVMI) in a cohort of 106 CKD patients across stages G1-5. Using a cross-lagged model, we paired each predictor (eGFR or LVMI) with subsequent outcome measurements, adjusting for previous values to ensure accuracy. Over a three-year follow-up period, we analyzed 257 paired LVMI and eGFR measurements.</p><p><strong>Results: </strong>At baseline, the median eGFR was 54 ml/min/1.73 m 2 , and the LVMI was 134 ± 48 g/m 2 , with a 62% prevalence of LVH. Our adjusted models revealed that a decrease in eGFR by 1 ml/min/1.73 m 2 predicted an increase in LVMI of 1.12 g/m 2 (95% CI: 0.71-1.54, P  < 0.001). In contrast, high LVMI did not predict a reduction in eGFR over time. This analysis highlights a significant risk of LVH worsening due to GFR loss, while the reverse risk does not achieve statistical significance.</p><p><strong>Conclusions: </strong>Although these observational analyses cannot establish causality, they suggest that the risk of cardiomyopathy driven by kidney disease in stable CKD patients may be more substantial than the risk of CKD progression driven by heart disease. This insight underscores the importance of monitoring kidney function to manage cardiovascular risk in CKD patients.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"986-992"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of empagliflozin on systemic haemodynamic function: three randomized, placebo-controlled trials.","authors":"Steffen F Nielsen, Camilla L Duus, Niels Henrik Buus, Jesper N Bech, Frank H Mose","doi":"10.1097/HJH.0000000000004007","DOIUrl":"10.1097/HJH.0000000000004007","url":null,"abstract":"<p><strong>Background: </strong>Sodium glucose cotransporter 2 inhibitors lower blood pressure. The underlying mechanisms are multifactorial and include effects on vascular function. We examined the systemic hemodynamic effects of empagliflozin in patients with type 2 diabetes mellitus (DM2) with and without chronic kidney disease (CKD) and in patients with nondiabetic CKD.</p><p><strong>Methods: </strong>Three double-blinded, randomized, placebo-controlled cross-over trials, including patients with DM2 and preserved renal function ( n  = 16), DM2 and CKD ( n  = 17) and nondiabetic CKD ( n  = 16). Participants were randomized to 4 weeks of empagliflozin 10 mg or placebo and crossed over after a 2-week washout. We measured brachial and central 24-h ambulatory blood pressure (ABP), pulse wave velocity (PWV), augmentation index (AIx@75), markers of nitric oxide and erythrocyte sodium sensitivity (ESS), a marker of endothelial glycocalyx function.</p><p><strong>Results: </strong>Empagliflozin reduced PWV [-0.16 m/s, 95% confidence interval (95% CI): -0.26; -0.06, P  = 0.002], AIx@75 (-2.17%, 95% CI: -3.31; -1.02, P  < 0.001) and brachial and central ABP in the combined study population ( n  = 49). Changes in PWV and AIx@75 correlated to changes in systolic brachial ABP. Markers of nitric oxide did not increase, but empagliflozin decreased ESS, which was correlated to an increase in haematocrit.</p><p><strong>Conclusion: </strong>Empagliflozin decreased arterial stiffness, mediated partly by a decrease in brachial ABP. We found no increase in nitric oxide activity, but ESS decreased. While this may be explained partly by a change in haematocrit, it could indicate an improvement in endothelial glycocalyx function.</p><p><strong>Trial registration: </strong>EU Clinical Trials Register 2019-004303-12, 2019-004447-80 and 2019-004467-50.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1021-1029"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of the Mediterranean-Dietary Approaches to Stop Hypertension diet vs. ultra-processed diet with health outcomes in type 2 diabetes and hypertension: new insights from a 12-month interventional study.","authors":"Tatiana Palotta Minari, Veridiana Vera de Rosso, Carolina Freitas Manzano, Marcelo Jamil Humsi, Louise Buonalumi Tácito Yugar, Luis Gustavo Sedenho-Prado, Tatiane de Azevedo Rubio, Lúcia Helena Bonalumi Tácito, Antônio Carlos Pires, José Fernando Vilela-Martin, Luciana Neves Cosenso-Martin, Juan Carlos Yugar-Toledo, Heitor Moreno, Luciana Pellegrini Pisani","doi":"10.1097/HJH.0000000000004061","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004061","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;There is ongoing debate about the optimal macronutrient and micronutrient proportions for treating type 2 diabetes (T2D) and hypertension. The objective of this study was to evaluate the dietary composition of patients participating in a 12-month interventional study with follow-up. Additionally, it aimed to evaluate the interactions and correlations between diet components and anthropometric markers, laboratory markers, and blood pressure (BP). Finally, perform a qualitative analysis of daily and postmeal satiety.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This experimental, analytical, and correlational study is a quaternary evaluation within a recently published longitudinal research. Eighty-four participants were divided into two groups: intervention: followed a Mediterranean-DASH diet for 12 months with follow-up at 15 months; control: no dietary changes. Parametric variables were compared using two-way ANOVA and Tukey post hoc test. Nonparametric variables were compared using Kruskal-Wallis with Dwass-Steel-Critchlow-Fligner post hoc test and Friedman with Durbin-Conover post hoc test. Parametric data were represented as mean ± standard deviation, nonparametric as median ± interquartile range. Linear regression was used for interaction/relation analysis, and Pearson test for correlation. Significance was P less than 0.05.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Initially, both groups consumed diets high in ultra-processed foods, rich in refined carbohydrates, saturated fats, and sodium. At the 12th visit and follow-up, the intervention group showed substantial improvement in diet quality and dietary requirements (P &lt; 0.05). The control group maintained or worsened their diet quality (P &lt; 0.05). At first, both groups reported high hunger and low satiety. By the 12th month, the intervention group showed significant improvements, with 88.6% reporting postmeal fullness and 75% experiencing daily satiety. Significant positive and negative correlations (P &lt; 0.05) were observed in both groups. In the control group, low-density lipoprotein cholesterol (LDL-C) was correlated with trans fats and proteins; high-density lipoprotein cholesterol (HDL-C) with polyunsaturated fats; total cholesterol (TC) with proteins and monounsaturated fats; and glycated hemoglobin (HbA1c) with fibers. In the intervention group, BMI was correlated with carbohydrates; HbA1c with total fats; LDL-C with carbohydrates; glucose with proteins; TC with total fats and carbohydrates; HDL-C with total fats, polyunsaturated fats, and saturated fats; glucose with monounsaturated fats (P &lt; 0.05). In the intervention group, BP, heart rate, plasma, and urinary sodium levels significantly improved over time (P &lt; 0.05). However, no strong correlations between sodium intake and these markers were observed (P &gt; 0.05). In contrast, the control group showed no significant changes in BP, heart rate, plasma, or urinary sodium levels over time (P &gt; 0.05), nor were there an","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring early vascular aging in youth: an expert consensus document from the Youth Vascular Consortium.","authors":"Jeanne Hersant, Ruan Kruger, Elisabetta Bianchini, Karsten Königstein, Manish D Sinha, Erzsébet V Hidvégi, Vimarsha Kodithuwakku, José Geraldo Mill, Alejandro Diaz, Yanina Zócalo, Daniel Bia, David Celermajer, Henner Hanssen, Madeleine Johansson, Giacomo Pucci, Mieczysław Litwin, Keeron Stone, Christopher J A Pugh, Lee Stoner, Elaine M Urbina, Rosa Maria Bruno, Peter M Nilsson, Rachel E Climie","doi":"10.1097/HJH.0000000000004039","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004039","url":null,"abstract":"<p><p>Since the conceptualization of early vascular aging (EVA) in 2008, significant efforts have been made to develop and improve its assessment. Initially lead by the investigation of arterial stiffness through pulse wave velocity (PWV), several additional vascular aging biomarkers have gained prominence in recent years. Despite expanding literature addressing methodological concerns associated with these biomarkers in youth, a standardized approach for clinical evaluation of EVA remains elusive, leaving pertinent gaps in understanding the optimal methodology. This article, resulting from international consensus efforts from the Youth Vascular Consortium, aims to provide an updated overview of methods available to measure EVA in youth and to discuss challenges in translating these methods into clinical practice.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating hypertension with single pill combinations: a simple strategy to save costs for the patients and payers.","authors":"Miriam Pikkemaat, Emily R Atkins, Anthony Rodgers, Aletta E Schutte","doi":"10.1097/HJH.0000000000004050","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004050","url":null,"abstract":"<p><strong>Objectives: </strong>Our aim was to compare direct costs for single pill combinations (SPCs) and free-drug combinations for hypertension treatment.</p><p><strong>Methods: </strong>We focused on Australia as a case study and reviewed total costs, and for the patient and government. We reviewed the Australian \"Pharmaceutical Benefits Scheme item drug map\" considering different thresholds for the government safety net. Total costs included medicine costs and pharmacy fees.</p><p><strong>Results: </strong>For patients, SPCs always cost less than free-drug combinations, with greatest savings for general patients before reaching safety net (averaging 30%). For government, SPCs cost on average less than free-drug combinations, for Concession Card holders both before (averaging 11%) and after reaching safety net (averaging 26%) and in general patients after safety net (averaging 11%). There was a slight increase in costs (16%) for the government for patients before reaching safety net. All findings were driven by savings in dispensing fees, the main cost of supply, also after the recent introduction of 60-day dispensing.</p><p><strong>Conclusion: </strong>Single pill combinations, instead of free-drug combinations, result in cost saving for both patient and government in almost all cases and often these savings are large. SPC cost savings should be factored into prescribing decisions, both for people receiving multiple pills and people starting treatment.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thermoneutral-housed rats demonstrate impaired perivascular adipose tissue and vascular crosstalk.","authors":"Melissa M Henckel, Ji Hye Chun, Leslie A Knaub, Gregory B Pott, Georgia E James, Kendall S Hunter, Robin Shandas, Lori A Walker, Jane E-B Reusch, Amy C Keller","doi":"10.1097/HJH.0000000000003948","DOIUrl":"10.1097/HJH.0000000000003948","url":null,"abstract":"<p><strong>Objective: </strong>Vascular pathology, characterized by impaired vasoreactivity and mitochondrial respiration, differs between the sexes. Housing rats under thermoneutral (TN) conditions causes vascular dysfunction and perturbed metabolism. We hypothesized that thoracic perivascular adipose tissue (tPVAT), a vasoregulatory adipose depot known to have a brown adipose tissue (BAT) phenotype, remodels to a mainly white adipose (WAT) phenotype in rats housed at TN, driving diminished vasoreactivity in a sex-dependent manner.</p><p><strong>Methods: </strong>Male and female Wistar rats were housed at either room temperature (RT) or TN. We measured changes in tPVAT morphology, vasoreactivity in vessels with intact tPVAT or transferred to tPVAT of the oppositely-housed animal, vessel stiffness, vessel mitochondrial respiration and cellular signaling.</p><p><strong>Results: </strong>Remodeling of tPVAT was observed in rats housed at TN; animals in this environment showed tPVAT whitening and displayed diminished aortae vasodilation ( P  < 0.05), different between the sexes. Juxtaposing tPVAT from RT rats onto aortae from TN rats in females corrected vasodilation ( P  < 0.05); this did not occur in males. In aortae of all animals housed at TN, mitochondrial respiration was significantly diminished in lipid substrate experiments ( P  < 0.05), and there was significantly less expression of phosphorylated endothelial nitric oxide synthase (peNOS) ( P  < 0.001).</p><p><strong>Conclusions: </strong>These data are consistent with TN-induced remodeling of tPVAT, notably associated with sex-specific blunting of vasoreactivity, diminished mitochondrial respiration, and altered cellular signaling.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"752-767"},"PeriodicalIF":3.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}